Dear Reader,
Welcome to this issue, where we delve into the remarkable strides made in medicine throughout 2025 in the Feature Story. Rheumatology has seen a transformative year, with breakthroughs in biologic therapies, precision medicine, and AI-driven care reshaping the landscape for conditions like RA, SLE, and PsA. Highlights include the approval of innovative agents such as dapirolizumab pegol and sonelokimab, alongside smart drug delivery systems and digital health integration—ushering in a new era of personalized treatment.
In our Focus section, we trace the evolution of hemophilia treatment—from early transfusions to cutting-edge biologics and gene therapies—culminating in the recent approval of marstacimab, a novel non-factor therapy that redefines care standards.
Beyond these features, the Industry Update explores the neuroprotective potential of statin-based therapies and strategies for managing treatment-resistant bipolar and anxiety disorders. Meanwhile, the Epoch section offers a thought-provoking look at the possible neurocognitive effects of sweeteners.
We hope this issue informs and inspires. Enjoy the read!
Dr. Feng Xue
MPH, PhD
Chief Editor, V.Pulse
To provide articles that match your interest, a V∙Pulse Reader Survey has been launched to collect your opinions on the preferred topics.
